Skip to content

Spain
United Kingdom
Europe
United States
Germany
Japan
The Middle East
Brazil
Italy
Canada
India
China
Taiwan
Mexico
Perú
Russia
Chile
Argentina
Turkey
Colombia
France

Europe

+34 96 390 53 10 Request Information

+34 96 390 53 10 Request Information

Europe

We guide you
Reproductive Health
- Specialists
  - ALICE
  - EMMA
  - ERA
  - EndomeTRIO
  - EMBRACE
  - CGT
  - NACE
  - PGT-A
  - PGT-M
  - POC
  - SAT
  - Newborn Screening
- Patients
  - ALICE
  - EMMA
  - ERA
  - EndomeTRIO
  - EMBRACE
  - CGT
  - NACE
  - PGT-A
  - PGT-M
  - SAT
  - POC
Diagnostics
About us
- Research & Igenomix Foundation
- About Igenomix
Webinars
Blog

Our Services > Oncodona

Oncodona

A complete test of genetic screening that analyzes 21 genes related to breast and ovarian cancer.

Overview
Features
How does it Work?
I’m a health specialist

igenomix

Early identification of predisposition to inherited cancer.

SAT Sperm aneuploidy test

Results in 30 days.

SAT Sperm aneuploidy test

Harmful mutations can be transmitted with a 50% probability.

What is Oncodona test?

Oncodona is the most advanced genetic test for early identification of predisposition to inherited cancer.
This test analyzes 21 genes related to breast and ovarian cancer in order to locate mutations that increase the risk of developing these types of cancer.
Oncodona uses Next Generation Sequencing (NGS) to analyze genetic information present in a panel of 21 genes, including BRCA1 and BRCA2 genes, in order to locate harmful mutations.

Indications
Benefits

Is Oncodona for you?

This test is recommended if:

You’ve been diagnosed with breast cancer and BRCA1 and BRCA2 negative genetic test. Oncodona can find a mutation in up to 4% of women.
A woman in your family has been diagnosed with breast and ovarian cancer.
You just want to know if you have any risk of developing breast and ovarian cancer.

Why use Oncodona?

The performance of the test, if positive, can be used to adopt follow-up and personalized early detection measures of the patient and their relatives.
A negative result means that the patient does not have an increased risk. In other words, their risk of suffering one of the types of cancer analysed by the test is the baseline risk of the population.

How does it work?

BROCHURE

Download

Do you have any questions?

Email*
Accept the privacy policy*
Accept the privacy policy*
CAPTCHA

Other services you may be interested in

CGT Carrier Genetic Test

CGT

Determines the risk of having a child with a genetic disease

More information

PGT-M Preimplantation Genetic Testing

PGT-M

Prevents the transmission of single gene disorders

More information

PGT-A Preimplantation Genetic Testing

PGT-A

Improves the chances of reproductive success by selecting chromosomally normal embryos

More information

Igenomix is in the media

WE GUIDE YOU

Fertility
Inherited diseases prevention
Healthy pregnancy

To see the accreditation certificate, associated technical annex and list of accredited tests, click on this link.

OUR SERVICES

Genetic solutions
For patients
How to send a sample?
User manual

ABOUT US

About Igenomix
Contact
Quality
Work with us

FOLLOW IGENOMIX

+ 96 390 53 10
Write us

Spain
United Kingdom
Europe
United States
Germany
Japan
The Middle East
Brazil
Italy
Canada
India
China
Taiwan
Mexico
Perú
Russia
Chile
Argentina
Turkey
Colombia
France

Europe

[2021] © Igenomix Privacy policy Quality policy Legal note Cookies policy News and Press

Request Information

First Name:
Last Name:
Email:
Phone:
Position:
Service interested in:
Comments:
Accept the privacy policy

reCAPTCHA demo: Simple page

We guide you
Reproductive Health
- Specialists
  - ALICE
  - EMMA
  - ERA
  - EndomeTRIO
  - EMBRACE
  - CGT
  - NACE
  - PGT-A
  - PGT-M
  - POC
  - SAT
  - Newborn Screening
- Patients
  - ALICE
  - EMMA
  - ERA
  - EndomeTRIO
  - EMBRACE
  - CGT
  - NACE
  - PGT-A
  - PGT-M
  - SAT
  - POC
Diagnostics
About us
- Research & Igenomix Foundation
- About Igenomix
Webinars
Blog
Europe
+34 96 390 53 10 Request Information